Related Experiment Video

Updated: May 18, 2026

Isolation and Culture Expansion of Tumor-specific Endothelial Cells
10:15

Isolation and Culture Expansion of Tumor-specific Endothelial Cells

Published on: October 14, 2015

Tumor endothelial markers as a target in cancer

Domenico Ribatti1, Girolamo Ranieri, Antonio Basile

  • 1University of Bari Medical School, Department of Basic Medical Sciences, Section of Human Anatomy and Histology, Piazza Giulio Cesare, 11, Bari, Italy. domenico.ribatti@uniba.it

Expert Opinion on Therapeutic Targets
|September 18, 2012
PubMed
Abstract

Insights

Developing effective anti-angiogenic cancer therapies requires validated biomarkers. Research is ongoing to identify predictive markers for treatment response and overcome resistance challenges in tumor therapy.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biomarker Discovery

Background:

  • Anti-angiogenic agents are utilized in cancer therapy but face challenges like resistance and lack of predictive biomarkers.
  • Tumor endothelial markers are crucial for targeting tumor vasculature and predicting treatment response.
  • Current pre-clinical studies offer numerous potential biomarkers, but none are fully validated for clinical use.

Purpose of the Study:

  • To review the current knowledge on tumor endothelial markers in anti-angiogenic therapy.
  • To discuss therapeutic strategies, resistance mechanisms, and the predictive value of biomarkers.
  • To explore future directions for identifying and utilizing effective biomarkers.

Main Methods:

  • Comprehensive literature review of pre-clinical and clinical studies on tumor endothelial markers.
  • Analysis of existing data on anti-angiogenic agents and their associated biomarkers.
  • Discussion of challenges and future strategies in biomarker research.

Main Results:

  • A wide array of potential tumor endothelial markers exist, including soluble molecules, circulating cells, and imaging markers.
  • No universally validated biomarkers are currently available to predict response to anti-angiogenic therapy.
  • Resistance mechanisms and the predictive value of identified markers require further investigation.

Conclusions:

  • Anti-angiogenesis represents a significant advancement in cancer treatment.
  • The identification and validation of predictive biomarkers for anti-endothelium therapy are critical challenges in anti-angiogenesis research.

More Related Videos

Monitoring Functionality and Morphology of Vasculature Recruited by Factors Secreted by Fast-growing Tumor-generating Cells09:03

Monitoring Functionality and Morphology of Vasculature Recruited by Factors Secreted by Fast-growing Tumor-generating Cells

Published on: November 23, 2014

A Matrigel-Based Tube Formation Assay to Assess the Vasculogenic Activity of Tumor Cells04:00

A Matrigel-Based Tube Formation Assay to Assess the Vasculogenic Activity of Tumor Cells

Published on: September 7, 2011

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
The Tumor Microenvironment02:17

The Tumor Microenvironment

Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
The Tumor Microenvironment02:17

The Tumor Microenvironment

Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...